Invensys rockets on rail disposal and cash return

Shares in technology group Invensys rocketed on Wednesday afternoon after the firm announced that it is to sell its rail division to Siemens, pay down its pension deficit and return a ton of cash to shareholders.

Shares in technology group Invensys rocketed on Wednesday afternoon after the firm announced that it is to sell its rail division to Siemens, pay down its pension deficit and return a ton of cash to shareholders.

The stock, which traded broadly flat for most of the session, was up 27.10% at 280p by the close of trade.

The company said that it has entered into an agreement to dispose of Invensys Rail to German engineering conglomerate Siemens for £1.742bn.

Invensys Rail provides software-based signalling, communication and control systems for the operation of trains.

"Following a strategic review which highlighted the likely consolidation in the global rail signalling market and the limited scope to increase the size of the Invensys Rail business, we have decided to refocus the Group around our industrial software, systems and control equipment business and, accordingly, to dispose of Invensys Rail," said Chief Executive Wayne Edmunds.

Due to the size of the proposal, the transaction requires the approval from Invensys shareholders (and other approvals) before it can complete. Completion is expected in the second quarter of next year.

The company also said that it has agreed with the trustee of its UK pension scheme to provide it with a "long-term pension solution and increased financial flexibility". This includes an up-front payment of £400m and a payment of £225m to a trust.

Edmunds said that the pension agreement "will result in the cessation of the current deficit reduction payments of £40-47m per annum and we anticipate that no further contributions will be payable into the scheme."

Furthermore, Invensys said it would return £625m in cash to shareholders, which equates to around 76p per share.

Edmunds added: "This transaction creates a more focused industrial software, systems and control equipment group with a significant exposure to higher growth and higher margin segments and the resources to invest in them. It also allows us to make substantial cost savings through a simplified organisational structure."

This simplified structure is expected to save the group £25m per annum by the end of 2014.

Recommended

Share tips of the week – 19 August
Share tips

Share tips of the week – 19 August

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
19 Aug 2022
How to invest in smart factories as the “fourth industrial revolution” arrives
Share tips

How to invest in smart factories as the “fourth industrial revolution” arrives

Exciting new technologies and trends are coming together to change the face of manufacturing. Matthew Partridge looks at the companies that will drive…
18 Aug 2022
How to invest today? Look to the past, not the future
Investment strategy

How to invest today? Look to the past, not the future

The past few years have seen so many changes to our way of life that many people said we had entered a “new normal”. But as it turns out, the new norm…
18 Aug 2022
A new legal headache for Haleon
Stocks and shares

A new legal headache for Haleon

Haleon, GSK’s former consumer-products arm, spun off last month, has made a dismal debut on the stockmarket.
17 Aug 2022

Most Popular

How to protect your wealth as inflation hits new record highs
Investment strategy

How to protect your wealth as inflation hits new record highs

UK inflation has hit a new record high of 10.1%. It's going to hurt, says Dominic Frisby. Here's how you can protect your wealth.
17 Aug 2022
How to cut your energy bill
Personal finance

How to cut your energy bill

The energy-price cap will almost double in the autumn. What does this mean for your money, and how can you alleviate the squeeze? Ruth Jackson-Kirby h…
17 Aug 2022
Are GSK’s legal troubles a threat to the firm’s survival?
Biotech stocks

Are GSK’s legal troubles a threat to the firm’s survival?

Pharmaceutical giant GlaxoSmithKline is facing legal action over heartburn drug Zantac that has seen billions wiped off its market value. Rupert Hargr…
16 Aug 2022